Form 4: MAIA Director Stan Smith Boosts Stake with Share Purchases

MAIA Biotechnology Director Stan Smith acquired 25,000 shares of common stock across two transactions in late November 2025, increasing his indirect beneficial ownership.

Summary

• Stan Smith, a Director of MAIA Biotechnology, Inc. (MAIA), reported two separate purchases of the company's common stock.
• On November 24, 2025, Mr. Smith purchased 10,000 shares of common stock at a weighted average price of $0.99 per share.
• The shares purchased on November 24, 2025, ranged in price from $0.9675 to $0.9899.
• On November 25, 2025, Mr. Smith purchased an additional 15,000 shares of common stock at a weighted average price of $0.98 per share.
• The shares purchased on November 25, 2025, ranged in price from $0.9550 to $1.05.
• Following these transactions, Mr. Smith beneficially owns a total of 1,349,289 shares of MAIA common stock.
• All reported securities are beneficially owned indirectly by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a director's significant open market purchases of company stock, indicating strong confidence in the company's future performance and valuation.

Positives

• A Director increasing their stake in the company signals confidence in its future prospects and valuation.
• The purchases were made at prices close to the current market value, indicating a belief in the stock's potential at these levels.

Future Outlook

NA

Industry Context

Insider buying, particularly by a director, is often interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its shares are undervalued or that significant positive developments are anticipated. This can be a stronger signal than purchases by other insiders, as directors typically have a broad view of the company's strategic direction and financial health.

Related Party Transactions

• The acquired securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993, indicating an indirect ownership structure involving a related party trust.

Stakeholder Impact

• Shareholders may view this insider buying as a strong vote of confidence from a director, potentially leading to increased investor interest and positive sentiment towards the stock.
• Employees and other stakeholders might also interpret this as a positive sign regarding the company's stability and future prospects.

Key Dates

Recommendation

The director's decision to significantly increase his stake in MAIA Biotechnology through open market purchases is a strong bullish signal. Insider buying suggests that those with the most intimate knowledge of the company's operations and future prospects believe the stock is undervalued or poised for growth. This action demonstrates confidence in the company's strategic direction and financial health, making it an attractive opportunity for investors.

Keywords

MAIA Biotechnology, MAIA, Insider Purchase, Director Stock Acquisition, Form 4, Common Stock, Stan Smith, Beneficial Ownership